BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20406945)

  • 1. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
    Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
    Viktorsson K; Shah CH; Juntti T; Hååg P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullén A
    Mol Oncol; 2016 May; 10(5):719-34. PubMed ID: 26827254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting SRC in mucinous ovarian carcinoma.
    Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
    Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of ER-Src axis in hormonal therapy resistance.
    Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
    Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
    Ling C; Chen G; Chen G; Zhang Z; Cao B; Han K; Yin J; Chu A; Zhao Y; Mao X
    Int J Cancer; 2012 Nov; 131(10):2411-9. PubMed ID: 22362357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P; Zhang W; Gorlick R; Kolb EA
    Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
    Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
    Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
    Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
    Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
    Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
    Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
    Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
    Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
    Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
    J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.